Endothelin receptor A blockade enhances taxane effects in prostate cancer

Ardavan Akhavan, Kevin H. McHugh, Georgi Guruli, Robert Bies, William C. Zamboni, Sandra Strychor, Joel B. Nelson, Beth Pflug

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

Endothelin (ET) 1 is important in the growth of prostate cancer cells through the activation of the endothelin A (ETA) receptor. ET receptor blockade is a new therapeutic target in treating advanced prostate cancer. This study investigates the impact of the combination of the ET A antagonist atrasentan (ABT-627) and taxane chemotherapy on prostate cancer cell survival in vitro and on the delay of prostate cancer in a xenograft mouse model. In vitro, PPC-1 cells transfected with an ET A-overexpressing vector were treated with ABT-627, paclitaxel/docetaxel, or both. Clonogenic viability and cell death assays were used to determine cell survival and apoptosis, respectively. ABT-627 and docetaxel combination treatment was used in vivo to treat mice with established ETA-overexpressing PPC-1 xenograft tumors, and tumor growth rates were assessed. Cell proliferation and vascularity were determined with Ki-67 and CD31 staining, respectively. Cells treated with combination therapy had significantly fewer viable cells and more programmed cell death than cells given monotherapy. Xenograft tumor growth rates were significantly lower in mice treated with combination therapy than in animals given a single agent. Ki-67 immunostaining demonstrated significantly fewer proliferative cells following combination therapy than following monotherapy. This study demonstrates ABT-627 to have additive antitumor effects when used in combination with taxane drugs both in vitro and in vivo.

Original languageEnglish (US)
Pages (from-to)725-732
Number of pages8
JournalNeoplasia
Volume8
Issue number9
DOIs
StatePublished - 2006
Externally publishedYes

Fingerprint

Endothelin A Receptors
Prostatic Neoplasms
docetaxel
Heterografts
Endothelins
Cell Survival
Cell Death
Growth
Therapeutics
Endothelin Receptors
Neoplasms
Endothelin-1
Paclitaxel
taxane
Cell Proliferation
atrasentan
Apoptosis
Staining and Labeling
Drug Therapy
Pharmaceutical Preparations

Keywords

  • ABT-627
  • Atrasentan
  • Endothelin
  • Prostate cancer
  • Taxane

ASJC Scopus subject areas

  • Cancer Research

Cite this

Akhavan, A., McHugh, K. H., Guruli, G., Bies, R., Zamboni, W. C., Strychor, S., ... Pflug, B. (2006). Endothelin receptor A blockade enhances taxane effects in prostate cancer. Neoplasia, 8(9), 725-732. https://doi.org/10.1593/neo.06388

Endothelin receptor A blockade enhances taxane effects in prostate cancer. / Akhavan, Ardavan; McHugh, Kevin H.; Guruli, Georgi; Bies, Robert; Zamboni, William C.; Strychor, Sandra; Nelson, Joel B.; Pflug, Beth.

In: Neoplasia, Vol. 8, No. 9, 2006, p. 725-732.

Research output: Contribution to journalArticle

Akhavan, A, McHugh, KH, Guruli, G, Bies, R, Zamboni, WC, Strychor, S, Nelson, JB & Pflug, B 2006, 'Endothelin receptor A blockade enhances taxane effects in prostate cancer', Neoplasia, vol. 8, no. 9, pp. 725-732. https://doi.org/10.1593/neo.06388
Akhavan A, McHugh KH, Guruli G, Bies R, Zamboni WC, Strychor S et al. Endothelin receptor A blockade enhances taxane effects in prostate cancer. Neoplasia. 2006;8(9):725-732. https://doi.org/10.1593/neo.06388
Akhavan, Ardavan ; McHugh, Kevin H. ; Guruli, Georgi ; Bies, Robert ; Zamboni, William C. ; Strychor, Sandra ; Nelson, Joel B. ; Pflug, Beth. / Endothelin receptor A blockade enhances taxane effects in prostate cancer. In: Neoplasia. 2006 ; Vol. 8, No. 9. pp. 725-732.
@article{6c27e87283404bdfb242e4a1313761e9,
title = "Endothelin receptor A blockade enhances taxane effects in prostate cancer",
abstract = "Endothelin (ET) 1 is important in the growth of prostate cancer cells through the activation of the endothelin A (ETA) receptor. ET receptor blockade is a new therapeutic target in treating advanced prostate cancer. This study investigates the impact of the combination of the ET A antagonist atrasentan (ABT-627) and taxane chemotherapy on prostate cancer cell survival in vitro and on the delay of prostate cancer in a xenograft mouse model. In vitro, PPC-1 cells transfected with an ET A-overexpressing vector were treated with ABT-627, paclitaxel/docetaxel, or both. Clonogenic viability and cell death assays were used to determine cell survival and apoptosis, respectively. ABT-627 and docetaxel combination treatment was used in vivo to treat mice with established ETA-overexpressing PPC-1 xenograft tumors, and tumor growth rates were assessed. Cell proliferation and vascularity were determined with Ki-67 and CD31 staining, respectively. Cells treated with combination therapy had significantly fewer viable cells and more programmed cell death than cells given monotherapy. Xenograft tumor growth rates were significantly lower in mice treated with combination therapy than in animals given a single agent. Ki-67 immunostaining demonstrated significantly fewer proliferative cells following combination therapy than following monotherapy. This study demonstrates ABT-627 to have additive antitumor effects when used in combination with taxane drugs both in vitro and in vivo.",
keywords = "ABT-627, Atrasentan, Endothelin, Prostate cancer, Taxane",
author = "Ardavan Akhavan and McHugh, {Kevin H.} and Georgi Guruli and Robert Bies and Zamboni, {William C.} and Sandra Strychor and Nelson, {Joel B.} and Beth Pflug",
year = "2006",
doi = "10.1593/neo.06388",
language = "English (US)",
volume = "8",
pages = "725--732",
journal = "Neoplasia",
issn = "1522-8002",
publisher = "Elsevier Inc.",
number = "9",

}

TY - JOUR

T1 - Endothelin receptor A blockade enhances taxane effects in prostate cancer

AU - Akhavan, Ardavan

AU - McHugh, Kevin H.

AU - Guruli, Georgi

AU - Bies, Robert

AU - Zamboni, William C.

AU - Strychor, Sandra

AU - Nelson, Joel B.

AU - Pflug, Beth

PY - 2006

Y1 - 2006

N2 - Endothelin (ET) 1 is important in the growth of prostate cancer cells through the activation of the endothelin A (ETA) receptor. ET receptor blockade is a new therapeutic target in treating advanced prostate cancer. This study investigates the impact of the combination of the ET A antagonist atrasentan (ABT-627) and taxane chemotherapy on prostate cancer cell survival in vitro and on the delay of prostate cancer in a xenograft mouse model. In vitro, PPC-1 cells transfected with an ET A-overexpressing vector were treated with ABT-627, paclitaxel/docetaxel, or both. Clonogenic viability and cell death assays were used to determine cell survival and apoptosis, respectively. ABT-627 and docetaxel combination treatment was used in vivo to treat mice with established ETA-overexpressing PPC-1 xenograft tumors, and tumor growth rates were assessed. Cell proliferation and vascularity were determined with Ki-67 and CD31 staining, respectively. Cells treated with combination therapy had significantly fewer viable cells and more programmed cell death than cells given monotherapy. Xenograft tumor growth rates were significantly lower in mice treated with combination therapy than in animals given a single agent. Ki-67 immunostaining demonstrated significantly fewer proliferative cells following combination therapy than following monotherapy. This study demonstrates ABT-627 to have additive antitumor effects when used in combination with taxane drugs both in vitro and in vivo.

AB - Endothelin (ET) 1 is important in the growth of prostate cancer cells through the activation of the endothelin A (ETA) receptor. ET receptor blockade is a new therapeutic target in treating advanced prostate cancer. This study investigates the impact of the combination of the ET A antagonist atrasentan (ABT-627) and taxane chemotherapy on prostate cancer cell survival in vitro and on the delay of prostate cancer in a xenograft mouse model. In vitro, PPC-1 cells transfected with an ET A-overexpressing vector were treated with ABT-627, paclitaxel/docetaxel, or both. Clonogenic viability and cell death assays were used to determine cell survival and apoptosis, respectively. ABT-627 and docetaxel combination treatment was used in vivo to treat mice with established ETA-overexpressing PPC-1 xenograft tumors, and tumor growth rates were assessed. Cell proliferation and vascularity were determined with Ki-67 and CD31 staining, respectively. Cells treated with combination therapy had significantly fewer viable cells and more programmed cell death than cells given monotherapy. Xenograft tumor growth rates were significantly lower in mice treated with combination therapy than in animals given a single agent. Ki-67 immunostaining demonstrated significantly fewer proliferative cells following combination therapy than following monotherapy. This study demonstrates ABT-627 to have additive antitumor effects when used in combination with taxane drugs both in vitro and in vivo.

KW - ABT-627

KW - Atrasentan

KW - Endothelin

KW - Prostate cancer

KW - Taxane

UR - http://www.scopus.com/inward/record.url?scp=33749045722&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33749045722&partnerID=8YFLogxK

U2 - 10.1593/neo.06388

DO - 10.1593/neo.06388

M3 - Article

C2 - 16984730

AN - SCOPUS:33749045722

VL - 8

SP - 725

EP - 732

JO - Neoplasia

JF - Neoplasia

SN - 1522-8002

IS - 9

ER -